Cargando…
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS
Dimethyl fumarate (DMF), recently approved as an oral immunomodulatory treatment for relapsing-remitting multiple sclerosis (MS), metabolizes to monomethyl fumarate (MMF) which crosses the blood–brain barrier and has demonstrated neuroprotective effects in experimental studies. We postulated that MM...
Autores principales: | Parodi, Benedetta, Rossi, Silvia, Morando, Sara, Cordano, Christian, Bragoni, Alberto, Motta, Caterina, Usai, Cesare, Wipke, Brian T., Scannevin, Robert H., Mancardi, Giovanni L., Centonze, Diego, Kerlero de Rosbo, Nicole, Uccelli, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503882/ https://www.ncbi.nlm.nih.gov/pubmed/25920452 http://dx.doi.org/10.1007/s00401-015-1422-3 |
Ejemplares similares
-
Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response
por: Parodi, Benedetta, et al.
Publicado: (2021) -
Bone Marrow Transfer in Relapsing-Remitting EAE Ameliorates Disease at First Remission, with No Synergistic Effect upon Co-Transplantation with Mesenchymal Stem Cells
por: Ferrara, Giovanni, et al.
Publicado: (2021) -
Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation
por: Giunti, Debora, et al.
Publicado: (2021) -
The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease?
por: Parodi, Benedetta, et al.
Publicado: (2021) -
Teriflunomide treatment reduces B cells in patients with MS
por: Gandoglia, Ilaria, et al.
Publicado: (2017)